Anamorelin was approved for production and marketing in Japan on 22 January 2021 for cancer cachexia in non-small-cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer. The authors describe the updates of anamorelin for cancer cachexia in Japan.

中文翻译：

---

日本癌症恶病质患者的阿拉莫林：更新。

Anamorelin于2021年1月22日在日本获批生产和销售，用于治疗非小细胞肺癌、胃癌、胰腺癌和结直肠癌的癌症恶病质。作者描述了日本阿拉莫林治疗癌症恶病质的最新情况。